



(51) International Patent Classification:

C12N 15/85 (2006.01) A61K 9/51 (2006.01)
C12N 15/63 (2006.01) A61K 45/06 (2006.01)
A61K 9/127 (2006.01) C12N 5/10 (2006.01)

(21) International Application Number:

PCT/US2022/074084

(22) International Filing Date:

22 July 2022 (22.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/203,451 23 July 2021 (23.07.2021) US

(71) Applicant: **SPARK THERAPEUTICS, INC.** [US/US];
3737 Market Street, Ste. 1300, Philadelphia, PA 19104
(US).

(72) Inventors: **ANGUELA, Xavier**; Passeig Reina Elisenda De, Montcada 2, àtic, 08034 Barcelona (ES). **CEJAS, Pedro**; 2000 Bridle Lane, Oreland, PA 19075 (US). **NAHVI, Ali**; 1053 Beaumont Road, Berwyn, PA 19312 (US). **YAZICIOGLU, Mustafa**; 2787 Highland Avenue, Broomall, PA 19008 (US). **ZHANG, Rui**; 62 Swanton Street, Unit B, Winchester, MA 01890 (US).

(74) Agent: **HEBER, Sheldon Orly et al.**; Ice Miller LLP, 1735 Market Street, Suite 3900, Philadelphia, PA 19103-7509 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

(54) Title: METHOD OF ENHANCING GENE THERAPY BY TARGETING CGAS-STING PATHWAY




Fig. 1

(57) Abstract: The present invention features method and composition that can be used to facilitate intracellular delivery of DNA to a subject. The provided methods and compositions employ a nanoparticle for intracellular DNA delivery and a cytosolic DNA-sensing inhibitor. The cytosolic DNA-sensing inhibitor is provided to decrease the subject's immune response that can be stimulated by the DNA.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))